TRIV-509
Pre-clinical- Indications
- Atopic dermatitis, Asthma
Company intelligence / Profile preview
Amagma Therapeutics
Waltham, Massachusetts, United Statesourcrowd.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Preclinical
01
Overview
Amagma developed a proprietary antibody discovery platform targeting enzyme-driven inflammatory diseases. The company advanced three preclinical programs and entered a strategic partnership with Innovent Biologics for development and commercialization in Greater China. In late 2023, Amagma merged with Modify Therapeutics to form Triveni Bio, which continues the pipeline as part of its broader precision medicine approach.[1][5][6]
- Therapeutic areas
- GastroenterologyPulmonologyDermatologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Innovent Biologics (option-to-license up to three programs from SEIZMIC™ platform for Greater China; global clinical manufacturing partner)
Beyond the preview
Go deeper on Amagma Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amagma Therapeutics.